Johnson & Johnson Company Profile (NYSE:JNJ)

About Johnson & Johnson (JNJ)

Johnson & Johnson logoJohnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: JNJ
  • CUSIP: 47816010
Key Metrics:
  • Previous Close: $123.51
  • 50 Day Moving Average: $125.13
  • 200 Day Moving Average: $118.21
  • 52-Week Range: $2,713,346,000.00 - $109.32
  • Trailing P/E Ratio: 20.76
  • Foreward P/E Ratio: 16.10
  • P/E Growth: 2.71
  • Market Cap: $335.13B
  • Outstanding Shares: 2,713,346,000
  • Beta: 0.74
  • Net Margins: 22.78%
  • Return on Equity: 25.61%
  • Return on Assets: 13.40%
  • Debt-to-Equity Ratio: 0.32%
  • Current Ratio: 2.73%
  • Quick Ratio: 2.36%

Analyst Ratings

Consensus Ratings for Johnson & Johnson (NYSE:JNJ) (?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 6 Buy Ratings
Consensus Rating:Hold (Score: 2.31)
Consensus Price Target: $125.41 (1.54% upside)

Analysts' Ratings History for Johnson & Johnson (NYSE:JNJ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
4/17/2017Barclays PLCReiterated RatingEqual Weight$125.00 -> $130.00LowView Rating Details
3/11/2017Jefferies Group LLCReiterated RatingHold$125.00 -> $132.00N/AView Rating Details
1/26/2017Wells Fargo & CoDowngradeOutperform -> Market Perform$112.28 -> $112.80N/AView Rating Details
1/25/2017Royal Bank of CanadaLower Price TargetOutperform$133.00 -> $128.00N/AView Rating Details
1/25/2017Goldman Sachs Group IncLower Price TargetNeutral$120.00 -> $115.00N/AView Rating Details
12/20/2016Credit Suisse Group AGReiterated RatingHoldN/AView Rating Details
11/28/2016Bank of America CorpReiterated RatingHold$126.00N/AView Rating Details
10/23/2016Societe GeneraleReiterated RatingHold$116.00N/AView Rating Details
10/21/2016ArgusReiterated RatingBuy$145.00N/AView Rating Details
9/11/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
8/19/2016Deutsche Bank AGReiterated RatingBuy$142.00N/AView Rating Details
7/20/2016BMO Capital MarketsReiterated RatingOutperform$132.00N/AView Rating Details
5/20/2016Raymond James Financial, Inc.Reiterated RatingOutperform$120.00N/AView Rating Details
5/20/2016Standpoint ResearchInitiated CoverageSell$94.00N/AView Rating Details
5/19/2016Morgan StanleyReiterated RatingHoldN/AView Rating Details
4/20/2016Piper Jaffray CompaniesBoost Price TargetNeutral$105.00 -> $106.00N/AView Rating Details
4/17/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
1/27/2016Independent Research GmbHSet Price TargetNeutral$108.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$95.00N/AView Rating Details
10/15/2015S&P Equity ResearchReiterated RatingBuy$120.00N/AView Rating Details
8/25/2015Cowen and CompanyReiterated RatingOutperform$114.00N/AView Rating Details
(Data available from 4/27/2015 forward)


Earnings History for Johnson & Johnson (NYSE:JNJ)
Earnings by Quarter for Johnson & Johnson (NYSE:JNJ)
Earnings History by Quarter for Johnson & Johnson (NYSE:JNJ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/18/2017Q1 17$1.77$1.83$18.02 billion$17.77 billionViewN/AView Earnings Details
1/24/2017Q416$1.56$1.58$18.28 billion$18.10 billionViewN/AView Earnings Details
10/18/2016Q316$1.65$1.68$17.71 billion$17.80 billionViewListenView Earnings Details
7/19/2016Q216$1.68$1.74$17.98 billion$18.50 billionViewListenView Earnings Details
4/19/2016Q116$1.65$1.68$17.50 billion$17.50 billionViewListenView Earnings Details
1/26/2016Q415$1.42$1.44$17.88 billion$17.80 billionViewListenView Earnings Details
10/13/2015Q315$1.45$1.49$17.47 billion$17.10 billionViewListenView Earnings Details
7/14/2015Q215$1.69$1.71$17.76 billion$17.80 billionViewListenView Earnings Details
4/14/2015Q115$1.54$1.56$17.31 billion$17.37 billionViewListenView Earnings Details
1/20/2015Q414$1.25$1.27$18.59 billion$18.30 billionViewListenView Earnings Details
10/14/2014Q314$1.42$1.50$18.41 billion$18.50 billionViewListenView Earnings Details
7/15/2014Q214$1.54$1.66$18.86 billion$19.50 billionViewN/AView Earnings Details
4/15/2014Q114$1.48$1.54$18.00 billion$18.10 billionViewN/AView Earnings Details
1/21/2014Q413$1.20$1.24$17.95 billion$18.40 billionViewN/AView Earnings Details
10/15/2013Q313$1.32$1.36$17.46 billion$17.60 billionViewN/AView Earnings Details
7/16/2013Q2 2013$1.39$1.48$17.71 billion$17.90 billionViewN/AView Earnings Details
4/16/2013Q1 2013$1.41$1.44$17.46 billion$17.50 billionViewN/AView Earnings Details
1/22/2013Q4 2012$1.17$1.19$17.67 billion$17.60 billionViewN/AView Earnings Details
10/16/2012$1.21$1.25ViewN/AView Earnings Details
7/17/2012$1.29$1.30ViewN/AView Earnings Details
4/17/2012$1.34$1.37ViewN/AView Earnings Details
1/24/2012$1.09$1.13ViewN/AView Earnings Details
10/18/2011$1.21$1.24ViewN/AView Earnings Details
7/19/2011$1.24$1.28ViewN/AView Earnings Details
4/19/2011$1.26$1.35ViewN/AView Earnings Details
1/25/2011$1.03$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Johnson & Johnson (NYSE:JNJ)
2017 EPS Consensus Estimate: $6.99
2018 EPS Consensus Estimate: $7.79
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$1.71$1.77$1.74
Q2 20171$1.86$1.86$1.86
Q3 20171$1.80$1.80$1.80
Q4 20171$1.59$1.59$1.59
Q1 20181$1.98$1.98$1.98
Q2 20181$2.04$2.04$2.04
Q3 20181$1.99$1.99$1.99
Q4 20181$1.78$1.78$1.78
(Data provided by Zacks Investment Research)


Current Dividend Information for Johnson & Johnson (NYSE:JNJ)
Most Recent Dividend:3/14/2017
Annual Dividend:$3.20
Dividend Yield:2.59%
Dividend Growth:6.70% (3 Year Average)
Payout Ratio:54.42% (Trailing 12 Months of Earnings)
45.07% (Based on This Year's Estimates)
41.72% (Based on Next Year's Estimates)
Track Record:54 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Johnson & Johnson (NYSE:JNJ)

Dividend History by Quarter for Johnson & Johnson (NYSE:JNJ)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Johnson & Johnson (NYSE:JNJ)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 65.30%
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)
Insider Trades by Quarter for Johnson & Johnson (NYSE:JNJ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Paulus StoffelsVPSell22,000$117.29$2,580,380.00View SEC Filing  
10/21/2016Charles PrinceDirectorBuy875$114.11$99,846.25View SEC Filing  
7/26/2016Dominic J CarusoVPSell41,146$125.01$5,143,661.46View SEC Filing  
7/22/2016Ronald A KapustaCAOSell2,935$125.01$366,904.35View SEC Filing  
6/7/2016Gary J PrudenVPSell9,735$116.03$1,129,552.05View SEC Filing  
6/7/2016Ronald A KapustaCAOSell3,000$115.79$347,370.00View SEC Filing  
5/10/2016Ronald A KapustaCAOSell3,957$114.77$454,144.89View SEC Filing  
2/17/2016Paulus StoffelsinsiderSell125,000$102.43$12,803,750.00View SEC Filing  
2/3/2016Peter FasoloVPSell151,385$104.12$15,762,206.20View SEC Filing  
10/23/2015Ronald A. KapustaCAOSell6,239$99.68$621,903.52View SEC Filing  
6/2/2015Charles PrinceDirectorBuy2,500$99.22$248,050.00View SEC Filing  
4/28/2015Paulus StoffelsInsiderSell187,250$100.73$18,861,692.50View SEC Filing  
9/10/2014James CullenDirectorSell2,446$104.12$254,677.52View SEC Filing  
5/5/2014Stephen CosgroveInsiderSell22,000$100.05$2,201,100.00View SEC Filing  
3/14/2014Peter FasoloVPSell6,824$93.15$635,655.60View SEC Filing  
8/14/2013Stephen CosgroveInsiderSell17,200$91.39$1,571,908.00View SEC Filing  
8/5/2013Michael UllmannVPSell16,140$93.68$1,511,995.20View SEC Filing  
7/25/2013Paulus StoffelsInsiderSell45,440$92.40$4,198,656.00View SEC Filing  
7/18/2013Dominic J CarusoCFOSell30,000$90.31$2,709,300.00View SEC Filing  
11/12/2012James CullenDirectorSell13,900$69.70$968,830.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Johnson & Johnson (NYSE:JNJ)
Latest Headlines for Johnson & Johnson (NYSE:JNJ)
DateHeadline logoJohnson & Johnson (JNJ) Getting Somewhat Positive Press Coverage, Study Finds - April 26 at 8:28 PM logoJohnson & Johnson's Medical Device Business: What Investors Need to Know - April 26 at 7:14 PM logoJohnson & Johnson's Medical Device Business: What Investors Need to Know - April 26 at 10:52 AM logoHere's Why Risk-Averse Investors May Want to Think Twice About Buying Johnson & Johnson - April 25 at 5:32 PM logoJohnson & Johnson Human Performance Institute Launches Corporate Athlete® Resilience Program - April 25 at 10:33 AM logoDanish Biotech Genmab Designed Johnson & Johnson's Fastest-Growing Drug - April 25 at 10:33 AM logoMorning News Call - India, April 25 - April 25 at 10:33 AM logoJohnson & Johnson: Modest Price Decline Presents Buying Opportunity - April 24 at 5:43 PM logoInteresting September Stock Options for JNJ - April 24 at 5:43 PM logoJohnson & Johnson to Host Pharmaceutical Business Review - April 24 at 5:43 PM logoWere Johnson & Johnson's Earnings Really That Bad? - April 24 at 5:43 PM logoWhy Achillion Pharmaceuticals, Noble Corp., and RLJ Lodging Trust Slumped Today - April 24 at 5:43 PM logoWere Johnson & Johnson's Earnings Really That Bad? - April 24 at 4:34 PM logoJohnson And Johnson: Seize It - April 24 at 11:13 AM logoIndia to expand access to J&J's TB drug this year - April 24 at 11:13 AM logoA Look at Johnson & Johnson’s Major Developments in 1Q17 - April 24 at 11:13 AM logoJ&J, Novartis and Takeda in talks for Brazil's Hypermarcas, sources say - April 24 at 11:13 AM logoEMERGING MARKETS-Brazil real, Mexico peso strengthen on French vote - April 24 at 11:13 AM logoBritain's back in favor for corporate deals despite Brexit - April 24 at 5:09 AM logoSouth Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade - April 23 at 6:29 PM logoU.S. FDA approves Samsung Bioepis' copy of J&J's Remicade - company - April 23 at 6:29 PM logoSomewhat Positive Media Coverage Very Likely to Impact Johnson & Johnson (JNJ) Stock Price - April 23 at 4:48 PM logoJohnson & Johnson (JNJ) Earns Hold Rating from BTIG Research - April 23 at 1:26 PM logoMeet Carbon, Who With Big Backers Google and General Electric Wants to Revolutionize Manufacturing - April 23 at 10:15 AM logoA Band-Aid for J&J - Barron's - April 22 at 5:37 PM logo3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings ... - Motley Fool - April 22 at 5:21 AM logo3 Reasons Gilead Sciences Is a Better Dividend Stock Than ... - Motley Fool - April 22 at 5:21 AM logo[$$] A Band-Aid for J&J - April 22 at 5:21 AM logoSamsung Bioepis wins FDA approval for rheumatoid arthritis drug that competes with Johnson & Johnson - April 22 at 12:13 AM logoJohnson & Johnson: Need Rock-Solid Dividend Growth? Look Here - April 21 at 5:59 PM logoHow Johnson & Johnson’s Medical Devices Segment Fared in 1Q17 - April 21 at 5:59 PM logoYour Key Highlights from JNJ’s 1Q17 Results - April 21 at 5:59 PM logoFDA OKs Samsung Bioepis's Biosimilar Version Of J&J's Remicade - April 21 at 5:59 PM logoBehind JNJ’s Medical Devices Growth Trajectory - April 21 at 5:59 PM logoLeerink Swann Comments on Johnson & Johnson's Q1 2018 Earnings (JNJ) - April 21 at 4:06 PM logo3 Things Johnson & Johnson Didn't Tell You in Its Q1 Earnings Update - April 21 at 3:54 PM logo(ISC)2 New Jersey Chapter Announces Marene Allison, VP and CISO for Johnson & Johnson as Keynote Speaker … - April 21 at 10:30 AM logoJohnson & Johnson’s Consumer Segment’s 1Q17 Earnings - April 21 at 10:30 AM logoWhat's in Store for AbbVie (ABBV) this Earnings Season? - April 21 at 10:30 AM logo3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson - April 21 at 7:57 AM logoJohnson & Johnson’s 1Q17 Earnings Miss Revenue Estimates - April 20 at 6:07 PM logoJohnson & Johnson’s 1Q17 Earnings: Changes in Its Growth Rate - April 20 at 6:07 PM logoJohnson & Johnson’s 1Q17 Segment-by-Segment Performance - April 20 at 6:07 PM logoJohnson & Johnson Target Actelion Could Exit Swiss Benchmark SMI Index This Month - April 20 at 11:12 AM logoJohnson & Johnson Wants to Use 3D Printing to Heal Broken Bones - April 20 at 11:12 AM logoJ&J target Actelion could exit Swiss benchmark SMI index this month - April 20 at 11:12 AM logo4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings - April 20 at 11:12 AM logoBetter Buy: Verizon Communications Inc. vs. Johnson & Johnson - April 20 at 11:12 AM logoQ2 2017 EPS Estimates for Johnson & Johnson Raised by Analyst (JNJ) - April 20 at 10:35 AM logoSeptember 15th Options Now Available For Johnson & Johnson (JNJ) - April 19 at 5:57 PM


Frequently Asked Questions for Johnson & Johnson (NYSE:JNJ)

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson declared a quarterly dividend on Tuesday, January 3rd. Stockholders of record on Tuesday, February 28th will be paid a dividend of $0.80 per share on Tuesday, March 14th. This represents a $3.20 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Friday, February 24th.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, April, 18th. The company reported $1.83 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.77 by $0.06. The firm earned $17.77 billion during the quarter, compared to analyst estimates of $18.02 billion. Johnson & Johnson had a return on equity of 25.61% and a net margin of 22.78%. The company's revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.68 EPS.

When will Johnson & Johnson make its next earnings announcement?

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson updated its FY17 earnings guidance on Tuesday, January, 24th. The company provided EPS guidance of $6.93-7.08 for the period, compared to the Thomson Reuters consensus estimate of $7.12. The company issued revenue guidance of $74.1-74.8 billion, compared to the consensus revenue estimate of $75.13 billion.

Where is Johnson & Johnson's stock going? Where will Johnson & Johnson's stock price be in 2017?

16 brokers have issued 1-year price objectives for Johnson & Johnson's stock. Their predictions range from $94.00 to $145.00. On average, they expect Johnson & Johnson's stock price to reach $125.41 in the next year.

What are analysts saying about Johnson & Johnson stock?

Here are some recent quotes from research analysts about Johnson & Johnson stock:

  • 1. BTIG Research analysts commented, "JNJ reported 1Q17 financial results before market open that were generally below expectations. We had expected growth within the Pharmaceuticals segment to become challenging during 2017, but the weakness experienced within key cardiovascular and metabolic franchises, Xarelto and Invokana, amplified the declines of the Remicade franchise and growth moderation of other leading drug brands. During our discussion of the Actelion merger, we highlighted that commercial catalysts for JNJ’s key drug brands were generally reflected by analyst estimates, putting more pressure on the company to unveil new catalysts within the R&D pipeline at the Pharma Business Review on May 17th. We remain Neutral." (4/19/2017)
  • 2. According to Zacks Investment Research, "J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, potential biosimilar competition and lower HCV revenues.  While Pfizer’s launch of biosimilar Remicade creates some uncertainty regarding the segment’s sales growth in 2017, we believe that the impact may be manageable. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. Estimates have remained mostly stable lately ahead of the Q4 earnings results. J&J has a positive record of earnings surprises in recent quarters. J&J's shares have surpassed that of large-cap pharma industry in 2016. However, headwinds persist in the form of generics and biosimilar competition and pricing pressure." (1/9/2017)
  • 3. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Who owns Johnson & Johnson stock?

Johnson & Johnson's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.41%), Bank of Montreal Can (0.25%), Russell Investments Group Ltd. (0.20%), PGGM Investments (0.12%), State of New Jersey Common Pension Fund D (0.12%) and Chevy Chase Trust Holdings Inc. (0.10%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta.

Who sold Johnson & Johnson stock? Who is selling Johnson & Johnson stock?

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Candriam Luxembourg S.C.A., Atalanta Sosnoff Capital LLC, Miller Howard Investments Inc. NY, Nationwide Fund Advisors, State of New Jersey Common Pension Fund D, PGGM Investments and Boston Advisors LLC. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso, Gary J Pruden, Paulus Stoffels and Ronald A Kapusta.

Who bought Johnson & Johnson stock? Who is buying Johnson & Johnson stock?

Johnson & Johnson's stock was bought by a variety of institutional investors in the last quarter, including Korea Investment CORP, Russell Investments Group Ltd., Acadian Asset Management LLC, Doyle Wealth Management, Fisher Asset Management LLC, Hexavest Inc., Janney Montgomery Scott LLC and Personal Capital Advisors Corp.

How do I buy Johnson & Johnson stock?

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Johnson & Johnson stock cost?

One share of Johnson & Johnson stock can currently be purchased for approximately $123.51.

Johnson & Johnson (JNJ) Chart for Thursday, April, 27, 2017

This page was last updated on 4/27/2017 by Staff